Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LB-208 |
| Synonyms | |
| Therapy Description |
LB-208 (AOP208) is an HTR1B antagonist, which potentially induces antitumor activity (Ann Oncol (2025) 36 (suppl_2) S625). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LB-208 | LB208|LB 208|AOP208|AOP-208|AOP 208 | LB-208 (AOP208) is an HTR1B antagonist, which potentially induces antitumor activity (Ann Oncol (2025) 36 (suppl_2) S625). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07914348 | Phase I | LB-208 | Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphoma (SERONCO-1) | Recruiting | ESP | 0 |